|
1
|
Wright JD, Chen L, Hou JY, Burke WM,
Tergas AI, Ananth CV, Neugut AI and Hershman DL: Association of
hospital volume and quality of care with survival for ovarian
cancer. Obstet Gynecol. 130:545–553. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lee YK, Chung HH, Kim JW, Song YS and Park
NH: Expression of phosphorylated Akt and hTERT is associated with
prognosis of epithelial ovarian carcinoma. Int J Clin Exp Pathol.
8:14971–14976. 2015.PubMed/NCBI
|
|
3
|
Stefanou DT, Bamias A, Episkopou H,
Kyrtopoulos SA, Likka M, Kalampokas T, Photiou S, Gavalas N,
Sfikakis PP, Dimopoulos MA and Souliotis VL: Aberrant DNA damage
response pathways may predict the outcome of platinum chemotherapy
in ovarian cancer. PLoS One. 10:e01176542015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bandera EV, Lee VS, Qin B,
Rodriguez-Rodriguez L, Powell CB and Kushi LH: Impact of body mass
index on ovarian cancer survival varies by stage. Br J Cancer.
117:282–289. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Littleton JT and Ganetzky B: Ion channels
and synaptic organization: Analysis of the Drosophila
genome. Neuron. 26:35–43. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Curran ME: Potassium ion channels and
human disease: Phenotypes to drug targets? Curr Opin Biotechnol.
9:565–572. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ji CD, Wang YX, Xiang DF, Liu Q, Zhou ZH,
Qian F, Yang L, Ren Y, Cui W, Xu SL, et al: Kir2.1 interaction with
Stk38 promotes invasion and metastasis of human gastric cancer by
enhancing MEKK2-MEK1/2-ERK1/2 signaling. Cancer Res. 78:3041–3053.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cheng YY, Wright CM, Kirschner MB,
Williams M, Sarun KH, Sytnyk V, Leshchynska I, Edelman JJ, Vallely
MP, McCaughan BC, et al: KCa1.1, a calcium-activated potassium
channel subunit alpha 1, is targeted by miR-17-5p and modulates
cell migration in malignant pleural mesothelioma. Mol Cancer.
15:442016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lastraioli E, Lottini T, Bencini L,
Bernini M and Arcangeli A: hERG1 potassium channels: Novel
biomarkers in human solid cancers. Biomed Res Int. 2015:8964322015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Patanè S: HERG-targeted therapy in both
cancer and cardiovascular system with cardiovascular drugs. Int J
Cardiol. 176:1082–1085. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Leanza L, Biasutto L, Managò A, Gulbins E,
Zoratti M and Szabò I: Intracellular ion channels and cancer. Front
Physiol. 4:2272013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
García-Quiroz J, García-Becerra R,
Santos-Martínez N, Barrera D, Ordaz-Rosado D, Avila E, Halhali A,
Villanueva O, Ibarra-Sánchez MJ, Esparza-López J, et al: In vivo
dual targeting of the oncogenic Ether-à-go-go-1 potassium channel
by calcitriol and astemizole results in enhanced antineoplastic
effects in breast tumors. BMC Cancer. 14:7452014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
D'Amico M, Gasparoli L and Arcangeli A:
Potassium channels: Novel emerging biomarkers and targets for
therapy in cancer. Recent Pat Anticancer Drug Discov. 8:53–65.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Balijepalli SY, Lim E, Concannon SP, Chew
CL, Holzem KE, Tester DJ, Ackerman MJ, Delisle BP, Balijepalli RC
and January CT: Mechanism of loss of Kv11.1 K+ current
in mutant T421M-Kv11.1-expressing rat ventricular myocytes:
Interaction of trafficking and gating. Circulation. 126:2809–2818.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fortunato A: The role of hERG1 ion
channels in epithelial-mesenchymal transition and the capacity of
riluzole to reduce cisplatin resistance in colorectal cancer cells.
Cell Oncol (Dordr). 40:367–378. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Becchetti A, Crescioli S, Zanieri F,
Petroni G, Mercatelli R, Coppola S, Gasparoli L, D'Amico M,
Pillozzi S, Crociani O, et al: The conformational state of hERG1
channels determines integrin association, downstream signaling, and
cancer progression. Sci Signal. 10(pii): eaaf32362017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sundby E, Han J, Kaspersen SJ and Hoff BH:
In vitro baselining of new pyrrolopyrimidine EGFR-TK inhibitors
with Erlotinib. Eur J Pharm Sci. 80:56–65. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fraley ME, Garbaccio RM, Arrington KL,
Hoffman WF, Tasber ES, Coleman PJ, Buser CA, Walsh ES, Hamilton K,
Fernandes C, et al: Kinesin spindle protein (KSP) inhibitors. Part
2: The design, synthesis, and characterization of
2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin
KSP. Bioorg Med Chem Lett. 16:1775–1779. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gao J, Wang G, Wu J, Zuo Y, Zhang J and
Chen J: Arsenic trioxide inhibits Skp2 expression to increase
chemosensitivity to gemcitabine in pancreatic cancer cells. Am J
Transl Res. 11:991–997. 2019.PubMed/NCBI
|
|
20
|
Qu X, Wang F, Zhang Y, Du Z, Ren J, Liu Z
and Zhang L: Biocompatible heterogeneous MOF-Cu catalyst used for
in vivo drug synthesis at targeted subcellular organelles. Angew
Chem Int Ed Engl. 19–Mar;2019.(Epub ahead of print). doi
org/10.1002/anie.201901760.
|
|
21
|
Park HH, Choi SW, Lee GJ, Kim YD, Noh HJ,
Oh SJ, Yoo I, Ha YJ, Koo GB, Hong SS, et al: A formulated red
ginseng extract inhibits autophagic flux and sensitizes to
doxorubicin-induced cell death. J Ginseng Res. 43:86–94. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhi D, Feng PF, Sun JL, Guo F, Zhang R,
Zhao X and Li BX: The enhancement of cardiac toxicity by
concomitant administration of Berberine and macrolides. Eur J Pharm
Sci. 76:149–155. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ortiz LM, Lombardi P, Tillhon M and
Scovassi AI: Berberine, an epiphany against cancer. Molecules.
19:12349–12367. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ayati SH, Fazeli B, Momtazi-Borojeni AA,
Cicero AFG, Pirro M and Sahebkar A: Regulatory effects of berberine
on microRNome in cancer and other conditions. Crit Rev Oncol
Hematol. 116:147–158. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang J, Yang S, Cai X, Dong J, Chen Z,
Wang R, Zhang S, Cao H, Lu D, Jin T, et al: Berberine inhibits EGFR
signaling and enhances the antitumor effects of EGFR inhibitors in
gastric cancer. Oncotarget. 7:76076–76086. 2016.PubMed/NCBI
|
|
26
|
Wang H, Li K, Ma L, Wu S, Hu J, Yan H,
Jiang J and Li Y: Berberine inhibits enterovirus 71 replication by
downregulating the MEK/ERK signaling pathway and autophagy. Virol
J. 14:22017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Puthdee N, Seubwai W, Vaeteewoottacharn K,
Boonmars T, Cha'on U, Phoomak C and Wongkham S: Berberine induces
cell cycle arrest in cholangiocarcinoma cell lines via inhibition
of NF-κB and STAT3 pathways. Biol Pharm Bull. 40:751–757. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hsu WH, Hsieh YS, Kuo HC, Teng CY, Huang
HI, Wang CJ, Yang SF, Liou YS and Kuo WH: Berberine induces
apoptosis in SW620 human colonic carcinoma cells through generation
of reactive oxygen species and activation of JNK/p38 MAPK and FasL.
Arch Toxicol. 81:719–728. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xing Y, Ding T, Wang Z, Wang L, Guan H,
Tang J, Mo D and Zhang J: Temporally-controlled
photothermal/photodynamic and combined therapy for overcoming
multidrug resistance of cancer by polydopamine nanoclustered
micelles. ACS Appl Mater Interfaces. 2–Apr;2019.(Epub ahead of
print). doi: 10.1021/acsami.9b00472. View Article : Google Scholar
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Capriglione S, Luvero D, Plotti F,
Terranova C, Montera R, Scaletta G, Schirò T, Rossini G, Benedetti
Panici P and Angioli R: Ovarian cancer recurrence and early
detection: May HE4 play a key role in this open challenge? A
systematic review of literature. Med Oncol. 34:1642017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yi H, Zheng X, Song J, Shen R, Su Y and
Lin D: Exosomes mediated pentose phosphate pathway in ovarian
cancer metastasis: A proteomics analysis. Int J Clin Exp Pathol.
8:15719–15728. 2015.PubMed/NCBI
|
|
33
|
Zheng F, Wu J, Tang Q, Xiao Q, Wu W and
Hann SS: The enhancement of combination of berberine and metformin
in inhibition of DNMT1 gene expression through interplay of SP1 and
PDPK1. J Cell Mol Med. 22:600–612. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang X, Wang N, Li H, Liu M, Cao F, Yu X,
Zhang J, Tan Y, Xiang L and Feng Y: Up-regulation of PAI-1 and
down-regulation of uPA are involved in suppression of invasiveness
and motility of hepatocellular carcinoma cells by a natural
compound berberine. Int J Mol Sci. 17:5772016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li D, Zhang Y, Liu K, Zhao Y, Xu B, Xu L,
Tan L, Tian Y, Li C, Zhang W, et al: Berberine inhibits
colitis-associated tumorigenesis via suppressing inflammatory
responses and the consequent EGFR signaling-involved tumor cell
growth. Lab Invest. 97:1343–1353. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chu SC, Yu CC, Hsu LS, Chen KS, Su MY and
Chen PN: Berberine reverses epithelial-to-mesenchymal transition
and inhibits metastasis and tumor-induced angiogenesis in human
cervical cancer cells. Mol Pharmacol. 86:609–623. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu X, Ji Q, Ye N, Sui H, Zhou L, Zhu H,
Fan Z, Cai J and Li Q: Berberine inhibits invasion and metastasis
of colorectal cancer cells via COX-2/PGE2 mediated JAK2/STAT3
signaling pathway. PLoS One. 10:e01234782015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yan M, Zhang K, Shi Y, Feng L, Lv L and Li
B: Mechanism and pharmacological rescue of berberine-induced hERG
channel deficiency. Drug Des Devel Ther. 9:5737–5747.
2015.PubMed/NCBI
|
|
39
|
Zhang K, Zhi D, Huang T, Gong Y, Yan M,
Liu C, Wei T, Dong Z, Li B and Yang B: Berberine induces hERG
channel deficiency through trafficking inhibition. Cell Physiol
Biochem. 34:691–702. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xia J, Wang H, Li S, Wu Q, Sun L, Huang H
and Zeng M: Ion channels or aquaporins as novel molecular targets
in gastric cancer. Mol Cancer. 16:542017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Arcangeli A and Becchetti A: Novel
perspectives in cancer therapy: Targeting ion channels. Drug Resist
Updat 21–22. 11–19. 2015. View Article : Google Scholar
|
